Most cancers become deadly by maintaining a low profile, only showing symptoms when they’re too advanced to treat. Ovarian and gastroesophageal cancers are among the most notorious for this sly disease progression, often leading to late-stage diagnoses.
Now an international team of researchers, including from The Rockefeller University’s Laboratory of Cellular and Structural Biology, have developed a highly sensitive blood test capable of detecting a key protein produced by cancer cells that shows promise for early detection. The findings were recently published in the journal Cancer Discovery.
Unlike many cancer tests that are limited in scope, expensive, or rely on invasive tissue sampling, this new method is a low-cost, multi-cancer detector that can pick up the presence of the telltale protein, known as LINE-1-ORF1p, in a tiny amount of blood in less than two hours.
Genetic copy and paste
Cancer biomarker detection is a young and growing field. There are a number of such biomarkers, but they can come with drawbacks. Some require surgical biopsies. Others are employed only after the emergence of symptoms, which can be too late for an effective intervention. Most are normal human proteins that have variability from person to person, making a single value hard to interpret. And many are targeted to a specific cancer, narrowing their range.
But recently, an important new biomarker for earlier detection may have emerged. That protein, known as LINE-1 ORF1p, came onto researchers’ radar about a decade ago. LINE-1 is a retrotransposon, a virus-like element present in every human cell that replicates through a copy-and-paste mechanism, resulting in a new copy in a new position in the genome. ORF1p is a protein it produces at high levels in cancer.
“Transposons are normally expressed in sperm and egg and during embryogenesis, so there are some circumstances where you have nonpathobiological expression of transposons,” says Rockefeller research associate professor John LaCava, a co-author on the paper, who specializes in LINE-1 research. “But otherwise, these ‘jumping genes’ are silenced within the genome, because their activity creates stress and insults in the cell.”
Most of the time, the body keeps LINE-1 in check. “There are layers of mechanisms that prevent LINE–1 from being expressed and producing ORF1p, so we can use the presence of the protein as a proxy for an unhealthy cell that no longer has control over its transcriptome,” LaCava notes. “You shouldn’t find ORF1p in the bloodstream of a healthy person.”
Over the past five years, he adds, “it’s become abundantly clear that these proteins become highly elevated in most cancers,” including many of the most common and lethal cancers of the esophagus, colon, lung, breast, prostate, ovaries, uterus, pancreas, and head and neck.
Because carcinoma cells make ORF1p from the onset of disease, researchers have long sought a sensitive, accurate test to detect ORF1p as early as possible. The ability to spot it in patients before a cancer has a chance to spread could potentially save lives.
Ultrasensitive assay
Rockefeller researchers teamed up with lead investigators from Mass General Brigham, the Wyss Institute for Biologically Inspired Engineering at Harvard University, and Dana-Farber Cancer Institute, along with other partnering institutions, to engineer a fast, low-cost assay able to detect ORF1p in plasma, which accounts for more than half of the content of human blood.
The new study uses a single-molecule-based detection technology known as Simoa that was developed by co-author David Walt, of Harvard. The Rockefeller team contributed custom nanobodies derived and engineered from llamas to act as capture reagents that ensnare the ORF1p protein and as sensitive probes to detect it.
“We developed these reagents as part of our mission to capture and describe the molecular associations of ORF1p with other proteins in colorectal cancers,” says LaCava. “We knew that most colorectal cancers have an abundance of LINE-1 proteins, so we reasoned that the interactions they form could be dysregulating normal cell functions in ways that benefit cancer. Isolating LINE-1 particles allowed us to have a closer look at these interactions. Later, it was clear that our collaborators at Harvard could make use of the same reagents for their developing biomarker assay, so we shared them.”
The researchers found that the assay was highly accurate at detecting ORF1p in the blood samples of patients with a variety of cancers, including ovarian, gastroesophageal, and colorectal cancers. It costs less than $3 to produce and returns fast results.
“We were shocked by how well this test worked across cancer types,” says lead author Martin Taylor, of the Department of Pathology at Massachusetts General Hospital.
The researchers also analyzed the plasma of 400 healthy people aged 20–90 who’d donated blood to the Mass General Brigham Biobank; ORF1p was undetectable in 97–99% of them. Of the five people who did have detectable ORF1p, the person with the highest level was found six months later to have advanced prostate cancer.
Be wary of spikes
Another potential use of the assay is monitoring how a patient is responding to cancer therapy. If a treatment is effective, the ORF1p level in the patient’s blood should drop, LaCava says. In one part of the study, the researchers studied 19 patients being treated for gastroesophageal cancer; in the 13 people who responded to the treatment, levels of ORF1p fell below the detection limit of the assay.
Tracking the protein could potentially be incorporated into routine healthcare, says LaCava. “During a healthy time in your life, you could have your ORF1p levels measured to establish a baseline. Then your doctor would just keep an eye out for any spikes in ORF1p levels, which could be indicative of a change in your state of health. While there might be some minor ORF1p fluctuations here and there, a spike would be a cause for a deeper investigation.”
From llamas to doctors
The study results also illustrate the immense potential of nanobody reagents generated through the study of interactomics, says Rout. Interactomics seeks to understand the dynamic interactions of the millions of individual components in a cell, particularly its proteins and nucleic acids. These interactions form macromolecular complexes that transmit information and control cellular behaviors. Pathogenic changes in these interactions underlie all diseases.
“There’s an essential need for much better tools to reveal and dissect interactomes that’s only beginning to be met,” Rout says. “To that end, we often collaborate with other institutions on the development of reagents such as our llama-derived nanobodies. The resulting products are not mere research tools—they have enormous potential in the hands of doctors.”

News
Tiny robots made from human cells heal damaged tissue
The ‘anthrobots’ were able to repair a scratch in a layer of neurons in the lab. Scientists have developed tiny robots made of human cells that are able to repair damaged neural tissue1. The [...]
Antimicrobial Resistance – A Global Concern
Key facts Antimicrobial resistance (AMR) is one of the top global public health and development threats. It is estimated that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to [...]
Advancing Pancreatic Cancer Treatment with Nanoparticle-Based Chemotherapy
Pancreatic cancer, a particularly lethal form of cancer and the fourth leading cause of cancer-related deaths in the western world, often remains undiagnosed until its advanced stages due to a lack of early symptoms. [...]
The ‘jigglings and wigglings of atoms’ reveal key aspects of COVID-19 virulence evolution
Richard Feynman famously stated, "Everything that living things do can be understood in terms of the jigglings and wigglings of atoms." This week, Nature Nanotechnology features a study that sheds new light on the evolution of the coronavirus [...]
AI system self-organizes to develop features of brains of complex organisms
Cambridge scientists have shown that placing physical constraints on an artificially-intelligent system—in much the same way that the human brain has to develop and operate within physical and biological constraints—allows it to develop features [...]
How Blind People Recognize Faces via Sound
Summary: A new study reveals that people who are blind can recognize faces using auditory patterns processed by the fusiform face area, a brain region crucial for face processing in sighted individuals. The study employed [...]
Treating tumors with engineered dendritic cells
Cancer biologists at EPFL, UNIGE, and the German Cancer Research Center (Heidelberg) have developed a novel immunotherapy that does not require knowledge of a tumor's antigenic makeup. The new results may pave the way [...]
Networking nano-biosensors for wireless communication in the blood
Biological computing machines, such as micro and nano-implants that can collect important information inside the human body, are transforming medicine. Yet, networking them for communication has proven challenging. Now, a global team, including EPFL [...]
Popular Hospital Disinfectant Ineffective Against Common Superbug
Research conducted during World Antimicrobial Awareness Week examines the effects of employing suggested chlorine-based chemicals to combat Clostridioides difficile, the leading cause of antibiotic-related illness in healthcare environments worldwide. A recent study reveals that a [...]
Subjectivity and the Evolution of AI Philosophy
An Historical Overview of the Philosophy of Artificial Intelligence by Anton Vokrug Many famous people in the philosophy of technology have tried to comprehend the essence of technology and link it to society and human [...]
How Lockdowns Shaped the Virus: AI Uncovers COVID-19’s Evolutionary Secrets
A new research study shows that human behavior, like lockdowns, influences the evolution of COVID-19, leading to strains that are more transmissible earlier in their lifecycle. Using artificial intelligence technology and mathematical modeling, a research [...]
Groundbreaking therapy approved: chances of cure for 7000 diseases:
Hereditary diseases are usually not curable. Now, however, an epochal turning point is taking place in medicine: For the first time ever, a therapy with the CRISPR/Cas9 gene scissors has received approval. According to [...]
Uncovering the Genetic Mystery: Why Some Never Show COVID-19 Symptoms
New study shows that common genetic variation among people is responsible for mediating SARS-CoV-2 asymptomatic infection. Have you ever wondered why some people never became sick from COVID-19? A study published recently in the journal Nature shows that common [...]
AI maps tumor geography for tailored treatments
Researchers have integrated AI approaches from satellite mapping and community ecology to develop a tool to interpret data obtained from tumor tissue imaging, with the aim of implementing a more individualized approach to cancer care. [...]
Lung cancer cells’ ‘memories’ suggest new strategy for improving treatment
A new understanding of lung cancer cells' "memories" suggests a new strategy for improving treatment, Memorial Sloan Kettering Cancer Center (MSK) researchers have found. Research from the lab of cancer biologist Tuomas Tammela, MD, Ph.D. [...]
Artificial sensor similar to a human fingerprint can recognize fine fabric textures
An artificial sensory system that is able to recognize fine textures—such as twill, corduroy and wool—with a high resolution, similar to a human finger, is reported in a Nature Communications paper. The findings may help improve the subtle [...]